Merix/Glaxo Cold Sore Cold War Ends With Settlement
This article was originally published in The Tan Sheet
Executive Summary
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation
You may also be interested in...
In Brief
CDER clarifies toll-free number labeling; FTC consent decree edit fails in Garden of Life case; NAD rules on Ranir’s Abridge ad; POM Wonderful, FTC plot appeals of ALJ decision; more news In Brief.
Merix Takes Road Less Traveled To Add Shingles Relief To OTC Monograph
Merix Pharmaceuticals has petitioned FDA to amend the external analgesic and skin protectant OTC monographs, to include an indication for the relief of symptoms of shingles and chicken pox for certain combinations of ingredients
Merix Takes Road Less Traveled To Add Shingles Relief To OTC Monograph
Merix Pharmaceuticals has petitioned FDA to amend the external analgesic and skin protectant OTC monographs, to include an indication for the relief of symptoms of shingles and chicken pox for certain combinations of ingredients